Applied Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Propel Bio Management, Leen Kawas, and Richard Kayne, along with Propel Bio Partners, have filed an amendment to their Schedule 13G, reporting a 4.17% beneficial ownership in Applied Therapeutics, Inc.
Alexandria Real Estate Equities and its subsidiaries have updated their beneficial ownership in Applied Therapeutics, Inc., reporting a combined stake primarily through warrants.
T. Rowe Price Investment Management, Inc. has disclosed a beneficial ownership of 14.9% in Applied Therapeutics Inc., holding 21,403,300 common shares as of September 30, 2025.
SCHEDULE 13G/A: T. Rowe Price Boosts Stake in Applied Therapeutics to 13.2%
T. Rowe Price Investment Management, Inc. has reported a significant beneficial ownership stake of 13.2% in Applied Therapeutics Inc., holding 18,683,990 shares.
The Vanguard Group has filed an amended Schedule 13G, revealing a 3.34% beneficial ownership stake in Applied Therapeutics Inc. as of June 30, 2025.
SCHEDULE 13G/A: BlackRock Discloses 3.7% Passive Stake in Applied Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 3.7% beneficial ownership stake in Applied Therapeutics Inc., held as a passive investment.
SCHEDULE 13G/A: Venrock Healthcare Capital Partners Group Discloses 4.1% Stake in Applied Therapeutics
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 4.1% in Applied Therapeutics, Inc.'s common stock as of March 31, 2025.
SCHEDULE 13G/A: Schonfeld Strategic Advisors Amends Stake in Applied Therapeutics, Reports 3.30% Passive Ownership
Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, disclosing a 3.30% beneficial ownership stake in Applied Therapeutics, Inc. as of March 31, 2025.
SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 11.0% Stake in Applied Therapeutics Inc.
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 11.0% of Applied Therapeutics Inc.'s common stock.
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, revealing a significant passive ownership stake of 8.9% in Applied Therapeutics Inc.'s common stock.
The Vanguard Group has filed a Schedule 13G, reporting a 5.06% beneficial ownership stake in Applied Therapeutics Inc as of March 31, 2025.
SCHEDULE 13G/A: Venrock Healthcare Funds Maintain Significant Stake in Applied Therapeutics, Disclosing 9.9% Beneficial Ownership
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of Applied Therapeutics, Inc.'s common stock as of December 31, 2024.
SCHEDULE 13G: Alyeska Investment Group Discloses 5.76% Stake in Applied Therapeutics, Including Warrants
Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has disclosed a beneficial ownership of 5.76% in Applied Therapeutics, Inc., comprising common stock and warrants.
SCHEDULE 13G: Schonfeld Strategic Advisors Discloses Significant 7.54% Stake in Applied Therapeutics
Schonfeld Strategic Advisors LLC has reported a 7.54% beneficial ownership stake in Applied Therapeutics, Inc., holding 8,769,640 shares of common stock as of December 31, 2024.
Perceptive Advisors LLC and its affiliates reported a beneficial ownership of 2.4% in Applied Therapeutics, Inc. as of December 31, 2024, indicating a substantial reduction from previous holdings.
Vestal Point Capital, LP and Ryan Wilder have jointly filed a Schedule 13G, revealing a passive beneficial ownership of 9.9% in Applied Therapeutics, Inc.'s common stock.
Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 0.0% beneficial ownership stake in Applied Therapeutics Inc. as of December 31, 2024.
Morgan Stanley and its subsidiary have filed an amended Schedule 13G, indicating they are no longer beneficial owners of more than five percent of Applied Therapeutics, Inc.'s common stock.
SCHEDULE 13G/A: BlackRock Discloses 8.0% Stake in Applied Therapeutics Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.0% of Applied Therapeutics Inc.'s common stock as of December 31, 2024.
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed a beneficial ownership of 7.6% of Applied Therapeutics, Inc.'s common stock as of December 31, 2024.
Franklin Resources, Inc. has filed an amended Schedule 13G, reporting a 1.7% beneficial ownership stake in Applied Therapeutics, Inc. as of December 31, 2024.